TY - JOUR
T1 - Molecular, Pathophysiological, and Clinical Aspects of Corticosteroid-Induced Neuropsychiatric Effects
T2 - From Bench to Bedside
AU - Sofía-Avendaño-Lopez, Sara
AU - Rodríguez-Marín, Angela Johanna
AU - Lara-Castillo, Mateo
AU - Agresott-Carrillo, Juanita
AU - Lara-Cortés, Luna Estefanía
AU - Sánchez-Almanzar, Juan Felipe
AU - Villamil-Cruz, Sophya
AU - Rojas-Rodríguez, Luis Carlos
AU - Ariza-Salamanca, Daniel Felipe
AU - Gaviria-Carrillo, Mariana
AU - Calderon-Ospina, Carlos Alberto
AU - Rodríguez-Quintana, Jesús
N1 - Publisher Copyright:
© 2024 by the authors.
PY - 2024/9
Y1 - 2024/9
N2 - Corticosteroids are frequently prescribed across medical disciplines, yet they are associated with various adverse effects, including neuropsychiatric symptoms, documented since their introduction over 60 years ago. The cellular mechanisms underlying neuropsychiatric symptoms are complex and somewhat obscure, involving multiple pathways. Notably, they include changes in excitability, cellular death of hippocampal and striatal neurons, and increased inflammation and oxidative stress. Clinical presentation varies, encompassing affective disorders (anxiety, euphoria, depression), psychotic episodes, and cognitive deficits. It is crucial to note that these manifestations often go unnoticed by treating physicians, leading to delayed detection of severe symptoms, complications, and underreporting. Discontinuation of corticosteroids constitutes the cornerstone of treatment, resolving symptoms in up to 80% of cases. Although the literature on this topic is scant, isolated cases and limited studies have explored the efficacy of psychotropic medications for symptomatic control and prophylaxis. Pharmacological intervention may be warranted in situations where corticosteroid reduction or withdrawal is not feasible or beneficial for the patient.
AB - Corticosteroids are frequently prescribed across medical disciplines, yet they are associated with various adverse effects, including neuropsychiatric symptoms, documented since their introduction over 60 years ago. The cellular mechanisms underlying neuropsychiatric symptoms are complex and somewhat obscure, involving multiple pathways. Notably, they include changes in excitability, cellular death of hippocampal and striatal neurons, and increased inflammation and oxidative stress. Clinical presentation varies, encompassing affective disorders (anxiety, euphoria, depression), psychotic episodes, and cognitive deficits. It is crucial to note that these manifestations often go unnoticed by treating physicians, leading to delayed detection of severe symptoms, complications, and underreporting. Discontinuation of corticosteroids constitutes the cornerstone of treatment, resolving symptoms in up to 80% of cases. Although the literature on this topic is scant, isolated cases and limited studies have explored the efficacy of psychotropic medications for symptomatic control and prophylaxis. Pharmacological intervention may be warranted in situations where corticosteroid reduction or withdrawal is not feasible or beneficial for the patient.
UR - http://www.scopus.com/inward/record.url?scp=85205033442&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85205033442&partnerID=8YFLogxK
U2 - 10.3390/biomedicines12092131
DO - 10.3390/biomedicines12092131
M3 - Review article
C2 - 39335644
AN - SCOPUS:85205033442
SN - 2227-9059
VL - 12
JO - Biomedicines
JF - Biomedicines
IS - 9
M1 - 2131
ER -